Liquidia Corp LQDA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$34.35 down $0.43, 1.24% at close Oct 16
Last close · Previous close $34.78
- Market cap
- At the Oct 16 close
- P/E ratio
- 24.71On last 12 months’ EPS
- Diluted EPS
- $1.39Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$34.35down $0.43, 1.24%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$34.78Oct 15
- Volume4.55MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume6.58MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $21.94 to $93.61; now $34.35
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
LQDA beat the S&P 500 in 3 of 6 periods.
| Period | LQDA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LQDA: down 49.8% S&P 500: up 1.5% | LQDA trailed the S&P 500 by 51.3 percentage points Trailed |
| 3M | LQDA: down 54.4% S&P 500: up 1.9% | LQDA trailed the S&P 500 by 56.3 percentage points Trailed |
| YTD | LQDA: down 0.4% S&P 500: up 12.8% | LQDA trailed the S&P 500 by 13.2 percentage points Trailed |
| 1Y | LQDA: up 48.2% S&P 500: up 16.8% | LQDA beat the S&P 500 by 31.4 percentage points Beat |
| Long term | ||
| 3Y | LQDA: up 463.1% S&P 500: up 81.5% +77.9% vs +22.0% a year | LQDA beat the S&P 500 by 381.6 percentage points Beat |
| 5Y | LQDA: up 973.4% S&P 500: up 83.1% +60.8% vs +12.9% a year | LQDA beat the S&P 500 by 890.3 percentage points Beat |
$10,000 invested in LQDA 5 years ago (Oct 15, 2021) would be worth about $107,344 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
LQDA beat the S&P 500 in 3 of 6 periods.
| Period | LQDA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | LQDA: down 49.8% S&P 500: up 1.2% | LQDA trailed the S&P 500 by 51.0 percentage points Trailed |
| 3M | LQDA: down 54.4% S&P 500: up 1.7% | LQDA trailed the S&P 500 by 56.1 percentage points Trailed |
| YTD | LQDA: down 0.4% S&P 500: up 11.9% | LQDA trailed the S&P 500 by 12.3 percentage points Trailed |
| 1Y | LQDA: up 48.2% S&P 500: up 15.5% | LQDA beat the S&P 500 by 32.7 percentage points Beat |
| Long term | ||
| 3Y | LQDA: up 463.1% S&P 500: up 75.0% +77.9% vs +20.5% a year | LQDA beat the S&P 500 by 388.1 percentage points Beat |
| 5Y | LQDA: up 973.4% S&P 500: up 71.2% +60.8% vs +11.4% a year | LQDA beat the S&P 500 by 902.2 percentage points Beat |
$10,000 invested in LQDA 5 years ago (Oct 15, 2021) would be worth about $107,344 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
All-time high
$91.03
Closing high on . Now 62.3% below that record.
Split-adjusted daily closes since Jul 26, 2018.
Stock splits
LQDA hasn’t split since its price history begins in 2018.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $450.91Mup 2,233.6%
- Net income
- $138.61M
- Diluted EPS
- $1.39
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $4.45M | −$31.03M | −$0.40 |
| Q4 FY24 (Dec 31, 2024) | $2.92M | −$38.51M | −$0.46 |
| Q1 FY25 (Mar 31, 2025) | $3.12M | −$38.37M | −$0.45 |
| Q2 FY25 (Jun 30, 2025) | $8.84M | −$41.58M | −$0.49 |
| Q3 FY25 (Sep 30, 2025) | $54.34M | −$3.53M | −$0.04 |
| Q4 FY25 (Dec 31, 2025) | $92.02M | $14.56M | $0.17 |
| Q1 FY26 (Mar 31, 2026) | $132.87M | $52.86M | $0.52 |
| Q2 FY26 (Jun 30, 2026) | $171.68M | $74.72M | $0.74 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $12.85M | −$34.58M | −$0.70 |
| FY22 (Dec 31, 2022) | $15.94M | −$41.02M | −$0.67 |
| FY23 (Dec 31, 2023) | $17.49M | −$78.50M | −$1.21 |
| FY24 (Dec 31, 2024) | $14.00M | −$128.29M | −$1.63 |
| FY25 (Dec 31, 2025) | $158.32M | −$68.92M | −$0.80 |
Margins
- Gross 92.5%
- Operating 37.4%
- Net 30.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $150.69MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$167.71MLast 12 months
- Capital spending$17.01MLast 12 months
- 33.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $6.63MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
0% of free cash flow
Balance sheet
- $287.69MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$182.90MAs of Jun 30, 2026
- Net cash$104.79MAs of Jun 30, 2026
- 2.31As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.94As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 149.6%Last 12 months
Over the last 12 months, Liquidia’s net income was 149.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 36.3%Last 12 months
Over the last 12 months, Liquidia’s net income was 36.3% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Liquidia Corp
Liquidia Corporation operates through the company’s subsidiaries, Liquidia Technologies, Inc. and RareGen. The Company, through Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company focused on the development and commercialization of products using its PRINT technology. It is focused on developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. RareGen provides commercialization for rare disease pharmaceutical products, such as Sandoz Inc.’s generic treprostinil for PAH. Liquidia Corporation is headquartered in Research Triangle Park, NC.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- North Carolina, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
LQDA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
LQDA stock FAQ
What is LQDA stock’s price today?
Liquidia (LQDA) traded at $34.35 at the close on , down $0.43 (1.24%) from the previous close of $34.78. Over the past 52 weeks it has traded between $21.94 and $93.61.
If you invested $1,000 in LQDA 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in LQDA on would be worth about $10,734 at the close on , a total return of +973.4%. The same $1,000 would be worth $1,482 if invested one year ago. Past performance doesn’t predict future returns.
What is LQDA’s P/E ratio?
LQDA trades at 24.7 times its diluted earnings over the four quarters to ($1.39 per share), at the close. (How the P/E ratio works.)
How much revenue does Liquidia make?
Liquidia reported $450.9 million of revenue over the four quarters to , up 2,233.6% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $171.7 million, up 1,842.7% from a year earlier.
Is Liquidia profitable?
Yes. Liquidia earned $138.6 million of net income over the four quarters to , a net margin of 30.7%, and its operating margin was 37.4% (what margins tell you).
What are LQDA’s earnings per share?
LQDA’s diluted earnings per share were $1.39 over the four quarters to , compared with −$1.80 in the twelve months before. The latest quarter (Q2 FY26) brought $0.74 per share, against −$0.49 a year earlier (how EPS works).
Does LQDA pay a dividend?
Liquidia hasn’t paid a dividend in the last twelve months.
What is LQDA’s 52-week high and low?
Over the past 52 weeks LQDA has traded as low as $21.94 and as high as $93.61. At $34.35 at the close on , it is 63.3% below that high and 56.6% above the low.
What is LQDA’s all-time high?
LQDA’s highest closing price was $91.03 on , adjusted for stock splits. At $34.35 at the close on , it is 62.3% below that record.
Has LQDA stock ever split?
No. LQDA hasn’t split since its price history begins in 2018.
How has LQDA stock performed?
Including dividends and measured to the close on , LQDA has returned −0.4% so far this year and +48.2% over the past year, and +973.4% over five years (+60.8% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Liquidia in?
Liquidia is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in North Carolina, USA.
What exchange does LQDA trade on?
Liquidia trades on the Nasdaq under the ticker symbol LQDA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.